Twenty/Twenty Therapeutics is a joint Venture of Verily Life Sciences, an Alphabet Company, and Santen Pharmaceuticals uniquely combining their expertise in technology and pharmaceuticals to develop connected ophthalmic therapeutics and personalized ocular digital health interventions.
Supported by more than 400 US and International patents, our groundbreaking devices and therapies will transform the way we approach eyecare – with the aspiration of making it more efficient and effective for everyone.
The aLens is an accommodating smart contact lens that utilizes dynamic electro-optics to change the power of the contact lens up to 3 diopters. This technology uniquely addresses the challenges of presbyopia without compromising the clarity of optics like many current solutions. To-date, the aLens has been evaluated on participants, in over 150 clinical sessions, and achieved visual acuity up to 20/16 at distance and near. The aLens achieves this with custom integrated circuits powered by a wirelessly rechargeable battery all miniaturized and embedded in a contact lens.